ZYTIGA ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 1 |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000945-29-IT (EUCTR) | 16/06/2016 | 04/11/2020 | Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) | Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS | Cushing’s syndrome in patients with adrenocortical carcinoma MedDRA version: 20.0;Level: PT;Classification code 10001388;Term: Adrenocortical carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE Product Name: ZYTIGA Product Code: [ZYTIGA] INN or Proposed INN: abiraterone acetato | AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Italy |